PHOST'IN: new class of "phostines"

AXLR



26 Octobre 2015

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

PHOST'IN is developing a new class of "phostines". of the 400 compounds already synthesized, a drug candidate qualified for treating glioblastoma is entering the regulatory preclinical phase.

 

CONTEXT
The first condition targeted by the project, Glioblastoma tumors (GBM) are the most common brain tumors, with 53,000 new cases every year around the world. The prognosis is generally very poor for people with this disease. The average survival rate is only about 15 months. No satisfactory treatment exists at this time. Treatment consists of surgically removing the tumor, followed by radiation therapy and chemotherapy. Clinical practitioners are waiting for new solutions to contain the tumors, thus facilitating surgical interventions and improving the benefits of treatment.

Phost’In is developing a new family of anti-cancer compounds whose effect has been demonstrated on glioblastoma.

The clinical objective is to provide a pre- and post-surgical anti-tumor and anti-migratory treatment to reinforce operability for patients and significantly improve the chances for survival as well as quality of life.

BENEFITS
The invasive nature of glioblastoma and the strong migration of tumor cells often lead to relapse occurring in zones that may be far from the original tumor. Neurosurgeons generally agree that reducing glioma infiltration using developed compounds would be a considerable improvement for global excision in patient treatment.

Beyond the major interest of this solution for treating glioblastoma, in-vivo results also demonstrate impact on the cancer cells’ ability to spread. This observation opens a broader range of application possibilities. The developed molecules also appear as potential inhibitors of the metastatic process, which makes it possible to target secondary tumors present in other types of cancer (melanoma, breast cancer, pancreas cancer, etc.).

The project maturation program helped contribute to the creation of a startup company.

 

APPLICATIONS
Oncology

Web site et vidéo : http://www.phostin.com

Download the offer Download the offer

Newsletter